Table 1_Expression levels of serum SCC, HE4, and TSGF in cervical cancer patients and thei

A retrospective study of 107 cervical cancer patients analyzed serum levels of SCC, HE4, and TSGF biomarkers before and after treatment. The data includes clinicopathological features and was used to develop a composite LogitScore for predicting recurrence risk within 3 years. The dataset was created by Yanan Wei and last updated on May 11, 2026.

Use Cases

• Predicting cervical cancer recurrence risk based on pretreatment serum biomarker levels.
• Analyzing the correlation between biomarker dynamics (ΔSCC, ΔHE4, ΔTSGF) and recurrence-free survival.
• Evaluating the predictive performance of composite scores like LogitScore against individual tumor markers.
• Identifying independent risk factors for recurrence, such as FIGO stage and HE4 levels.

Strengths

• Includes data for 107 patients with pathologically confirmed cervical cancer.
• Measures three serum biomarkers (SCC, HE4, TSGF) both pre- and post-treatment.
• Reports a high predictive performance for the composite LogitScore with an AUC of 0.983.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The model was developed and evaluated on the same cohort of 107 patients, requiring external validation.

Provenance

Source

figshare

Collection Method

Retrospective analysis of patient records and serum biomarker measurements.

Freshness

Last updated 2026-05-11 05:28:37; freshness should be verified.